Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $18.7 million.

  • Heron Therapeutics' Cash from Investing Activities rose 198.69% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.9 million, marking a year-over-year increase of 2235.26%. This contributed to the annual value of $18.7 million for FY2024, which is 4.00% up from last year.
  • As of FY2024, Heron Therapeutics' Cash from Investing Activities stood at $18.7 million, which was up 4.00% from $18.0 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Cash from Investing Activities ranged from a high of $209.0 million in FY2020 and a low of -$3.3 million during FY2022.
  • In the last 3 years, Heron Therapeutics' Cash from Investing Activities had a median value of $18.0 million in 2023 and averaged $11.1 million.
  • As far as peak fluctuations go, Heron Therapeutics' Cash from Investing Activities surged by 1,059.26% in 2020, and later crashed by 110.16% in 2022.
  • Heron Therapeutics' Cash from Investing Activities (Yearly) stood at $209.0 million in 2020, then crashed by 84.34% to $32.7 million in 2021, then plummeted by 110.16% to -$3.3 million in 2022, then spiked by 641.37% to $18.0 million in 2023, then climbed by 4.00% to $18.7 million in 2024.